AxoGen Stock News

ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a

AxoGen, Inc. (NASDAQ:AXGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive O

AxoGen (AXGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.06 per share a year ago.

ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t

AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9%

The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,

ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen, Inc. (NASDAQ:AXGN ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, CEO & President Pete Mariani - EVP & CFO

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t